Opendata, web and dolomites

SHIGETECVAX SIGNED

Early clinical development of a live, attenuated combination vaccine against Shigella and ETEC diarrhoea

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SHIGETECVAX project word cloud

Explore the words cloud of the SHIGETECVAX project. It provides you a very rough idea of what is the project "SHIGETECVAX" about.

shigetec    mucosal    administration    disruption    reactogenic    live    molecular    oral    induce    vaccines    natural    disease    solution    shigella    vaccine    shigellosis    advantage    generations    diarrhoea    advancing    too    expertise    gut    candidates    failed    antibodies    adults    material    safer    additional    elimination    first    although    protection    infections    attempts    surface    toxin    pathogens    multiple    entails    immunodominant    populations    invasion    radically    trial    reduce    costly    caused    pillars    immunity    almost    immune    neutralizing    ing    immunogenicity    manufacture    lps    clinical    bangladesh    huge    rational    recognition    possibly    complementary    designed    safety    lmics    detoxified    antigen    sero    critical    vaccination    antigens    efforts    enteric    shared    protecting    human    invasiveness    doses    blocking    closely    virulence    etec    attenuated    serotypes    pathogen    epidemiology    cell    endemic    burden   

Project "SHIGETECVAX" data sheet

The following table provides information about the project.

Coordinator
EUROPEAN VACCINE INITIATIVE EWIV 

Organization address
address: VOSSSTRASSE 2 GEB 4040
city: HEIDELBERG
postcode: 69115
website: http://www.euvaccine.eu/

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 0 €
 EC max contribution 8˙603˙989 € (0%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2018-Two-Stage-RTD
 Funding Scheme RIA-LS
 Starting year 2019
 Duration (year-month-day) from 2019-09-01   to  2024-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    EUROPEAN VACCINE INITIATIVE EWIV DE (HEIDELBERG) coordinator 359˙755.00
2    EVELIQURE BIOTECHNOLOGIES GMBH AT (WIEN) participant 5˙024˙401.00
3    INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH BANGLADESH BD (DHAKA) participant 1˙924˙713.00
4    GOETEBORGS UNIVERSITET SE (GOETEBORG) participant 749˙842.00
5    PATH US (SEATTLE) participant 545˙277.00

Map

 Project objective

Although vaccination is an effective way to reduce the huge disease burden associated with diarrhoea caused by enteric pathogens, many attempts to develop vaccines for shigellosis and ETEC infections have failed and a number of current approaches are too complex and costly to provide an adequate solution for LMICs. This Consortium is dedicated to advancing a radically new approach against Shigella and ETEC based not on the immunodominant, but highly variable Shigella LPS O-antigen, target of almost all past and current vaccine development efforts. There are four pillars on which the ShigETEC vaccine has been designed: (i) Elimination of the LPS O-antigen to allow recognition of multiple antigens on the cell surface that are shared among different serotypes of Shigella and are increasingly being recognized as important in protection from shigellosis. These antigens are also closely related to those of ETEC and may also help in protecting against that pathogen as well. (ii) Elimination of the invasiveness of Shigella by disruption of the invasion complex resulting in a much safer/less reactogenic oral vaccine that can take advantage of gut mucosal immunity, possibly allowing administration of high vaccine doses and therefore addresses the low immunogenicity seen with other live attenuated vaccine candidates. (iii) Addition of detoxified toxin antigens of ETEC that will induce neutralizing/blocking antibodies to these critical virulence factors. (iv) Rational molecular design of ShigETEC will allow future generations of vaccines to include additional antigens for other pathogens. The work programme entails manufacture of clinical trial material, first-in-human testing for safety and immunogenicity in non-endemic adults, a sero-epidemiology study to learn about natural immune response to the vaccine, and importantly testing the vaccine in endemic populations. The Consortium comprises partners from EU and Bangladesh that bring along highly complementary expertise.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SHIGETECVAX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SHIGETECVAX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More